Guidewire Software Inc. Common Stock vs Illumina, Inc. — how do they compare? Guidewire Software Inc. Common Stock trades at $165.27 (market cap $13.59B), while Illumina, Inc. trades at $271.77 (market cap $40.95B). The key difference: Illumina, Inc. is far larger — about 3× Guidewire Software Inc. Common Stock's market cap, and Illumina, Inc. is trading nearer its 52-week high, Guidewire Software Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Guidewire Software Inc. Common Stock for 0 Days and Illumina, Inc. for 84 Days on average.
| GWRE | ILMN | |
|---|---|---|
Market Cap | $13.59B | $40.95B |
Volume | 838,274 | 1,893,606 |
Sector | Technology | Health |
52-Week High | $254.23 | $293.69 |
52-Week Low | $102.69 | $93.00 |
Typical Hold Time | 0 Days | 84 Days |
Enterprise Value | $13.55B | $42.31B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Illumina (ILMN) trades at $271.76, down 1.77% today but near its 52-week high of $278.99. The stock has surged 94.9% YTD, supported by strong earnings beats and positive technical momentum. Recent quarterly results exceeded expectations with Q2 2026 EPS of $1.31 beating the $1.23 estimate. The company shows improving fundamentals with 2025 net income of $850 million and robust operating cash flow of $1.08 billion.
ILMN presents growth potential through AI integration and S&P 500 inclusion, but faces risks from China headwinds and elevated valuations. Analyst consensus remains bullish with 54% buy ratings, though the $241 consensus price target suggests limited upside. Key catalysts include continued sequencing growth and margin expansion, while competition and cost volatility remain concerns.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Guidewire Software Inc. develops InsuranceSuite Cloud, a software platform used by property and casualty insurers for policy administration, billing, and claims processing.
Read more on GWRE →Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →